|
 |
| home > epc > winter 2003 > why the us fda is rethinking 21 cfr part 11 and what can we do now? |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Much discussion has ensued regarding 21 CFR Part 11, the FDA's withdrawal of the guidances, and the intent of the new guidance. Rather than revisiting this topic I intend to expound upon why the FDA is revisiting Part 11, what our industry did to exacerbate the situation, and how we can move forward rationally while the FDA redefines the scope of Part 11.
Why is the US FDA Rethinking Part 11?
When the regulation was first issued there was a lot of discussion but little actual movement towards implementation. Then the first few warning letters started to emerge and people began to look for answers on how to proceed with compliance. As with most compliance processes in the life sciences sector, we started by making lists of affected systems so that we could evaluate risks and assign priorities. We called it 'compliance assessment'.
Not sure what was going to be relevant and what wasn't, we started by listing all computer systems we could think of. After all, if a system did not have to be Part 11-compliant we could take it off the list, right? Lack of experience with Part 11 and the evolution of understanding of electronic records unfortunately resulted in many irrelevant systems remaining on the lists. People could rationalise that any information in a computing system was somehow an electronic record. Valuable resources were spent trying to establish remediation processes for computer systems that did not really use electronic records!
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
